Clinical Trials
8 trialsNCT03937830 2026-05-22
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT07391670 2026-05-15
IMFINZI-subQ
AstraZeneca
Phase 1 Recruiting
NCT07081633 2026-05-12
TREMENDOUS-2
AstraZeneca
Phase 2 Active not recruiting
NCT06921785 2026-05-11
ARTEMIDE-HCC01
AstraZeneca
Phase 3 Recruiting
NCT05027425 2026-05-06
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
University of Cincinnati
Phase 2 Terminated
NCT07122089 2026-05-05
IOSPHERE
Center Eugene Marquis
Phase 2 Recruiting
NCT03482102 2026-05-04
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT07166406 2026-05-04
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting